Upgrades

We maintain our HOLD rating on the stock

Welspun Living Limited’s (WLL’s) Q2FY2025 numbers were mixed, with revenue beating estimates and growing by 14.5% y-o-y to Rs. 2,873 crore, while EBITDA margin fell by 182 bps y-o-y to 12.4% and missed the mark. PAT stood flat y-o-y at Rs. 202 crore.

Company reported a Revenue of Rs. 30,673 crore (down 6.4% y-o-y). Volume offtake decreased 3.5%% y-o-y while the blended realizations fell 5.8% y-o-y. Both the segments, FSA and e-auction witnessed a volume and pricing decline.

Sun Pharmaceutical Industries reported a revenue of ?13,291 crore for the quarter, reflecting a 9% year-over-year increase and a 5% rise quarter-over-quarter. This figure surpassed our estimates by 2%, despite experiencing price reductions in Taro’s portfolio and in Japan.

Revenues grew by 14.9% y-o-y to Rs. 4,605 crore with margins expansion of 510 bps y-o-y. Results outperformed expectations on margin front. Higher revenue and margin led to PAT growth of 38% y-o-y to Rs. 1092 crore. Revenue growth guidance is at 15% and OPM at 23-25% for FY2025.

Revenues reached Rs. 696 crore, marking a 16% y-o-y increase and a 10% q-o-q rise, with
exports growing by 44% y-o-y.

Quarterly Update Q2FY25